1 Ocak 2022 Dergi makalesi Açık Erişim

Kalkanli Tas, Sevgi; Uzunoglu, Merve Saide; Uzunoglu, Aylin Seher; Kirkik, Duygu; Altunkanat, Derya; Kalkanli, Nevin

Dublin Core

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Kalkanli Tas, Sevgi</dc:creator>
  <dc:creator>Uzunoglu, Merve Saide</dc:creator>
  <dc:creator>Uzunoglu, Aylin Seher</dc:creator>
  <dc:creator>Kirkik, Duygu</dc:creator>
  <dc:creator>Altunkanat, Derya</dc:creator>
  <dc:creator>Kalkanli, Nevin</dc:creator>
  <dc:date>2022-01-01</dc:date>
  <dc:description>Coronavirus disease 2019 (COVID-19) pandemic has been an important global interest that affected millions of people, and it requires a deep investigation of the disease immunology for developing further therapeutic applications. Adoptive T cell therapy promises to address T cell-dependent immune dysregulation in COVID-19 patients by the generation of specific T cell clones against virus-specific antigens. Additionally, targeting B cell-dependent protection through COVID-19 vaccines, which have been developed in the recent year, possessed sufficient prevention for spreading the virus, since the cases and deaths related to COVID-19 tend to decrease after the vaccination. However, adoptive cell therapies are now encouraging scientists to deal with pathological challenges like inadequate T cell-dependent immune response or lymphopenia, since they are the most frequent outcome of severe infection, especially in immunocompromized patients. In this review, the current knowledge of immunopathology of COVID-19 was aimed to be highlighted along with the T cell responses against SARS-CoV-2 to comprise a basis for therapeutics. Moreover, current therapeutics and treatment strategies for COVID-19 were discussed to evaluate possible agents. Furthermore, the use of adoptive T cell therapy representing an emerging therapeutic approach was purposed to be presented comprehensively against SARS-CoV-2 infection. Even though further studies are needed to fully understand T cell response against SARS-CoV-2 in order to develop therapies to provide long term and efficient protection, adoptive cell therapies now meet the demand for a large population of people who suffer immunocompromization, considering the previous usage of the technique for different infectious diseases.</dc:description>
  <dc:identifier>https://aperta.ulakbim.gov.trrecord/256005</dc:identifier>
  <dc:identifier>oai:aperta.ulakbim.gov.tr:256005</dc:identifier>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>http://www.opendefinition.org/licenses/cc-by</dc:rights>
  <dc:source>TURKISH JOURNAL OF BIOLOGY 46(2) 105-117</dc:source>
  <dc:title>Adoptive T-cell therapies to overcome T cell-dependent immune dysregulations in COVID-19</dc:title>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:type>publication-article</dc:type>
</oai_dc:dc>